Hanmi Pharmaceutical Co., Ltd.’s in-house developed long-acting glucacon-like peptide-1 receptor agonist efpeglenatide has received the Ministry of Food and Drug Safety’s approval to begin a Phase III trial, moving closer to commercialization of the first one of several obesity pipeline projects it is focusing on as a next growth engine, the Hanmi Obesity Pipeline (HOP).
The approval of the IND, submitted in July, came rapidly as the Korean pharma firm benefited from the global innovative products on fast track (GIFT) system operated by the drug ministry, which helped the company to secure an opportunity to closely communicate with the regulator on clinical trial and approval
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?